Idiopathic anaphylaxis

Idiopathic anaphylaxis (IA) or spontaneous anaphylaxis is a diagnosis of exclusion when no cause can be identified. The exact incidence and prevalence of IA are not known. The clinical manifestations of IA are similar to other known causes of anaphylaxis. A typical attack is usually acute in onset a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental allergy 2019-07, Vol.49 (7), p.942-952
Hauptverfasser: Bilò, Maria Beatrice, Martini, Matteo, Tontini, Chiara, Mohamed, Omar E., Krishna, Mamidipudi T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 952
container_issue 7
container_start_page 942
container_title Clinical and experimental allergy
container_volume 49
creator Bilò, Maria Beatrice
Martini, Matteo
Tontini, Chiara
Mohamed, Omar E.
Krishna, Mamidipudi T.
description Idiopathic anaphylaxis (IA) or spontaneous anaphylaxis is a diagnosis of exclusion when no cause can be identified. The exact incidence and prevalence of IA are not known. The clinical manifestations of IA are similar to other known causes of anaphylaxis. A typical attack is usually acute in onset and can worsen over minutes to a few hours. The pathophysiology of IA has not yet been fully elucidated, although an IgE‐mediated pathway by hitherto unidentified trigger/s might be the main underlying mechanism. Elevated concentrations of urinary histamine and its metabolite, methylimidazole acetic acid, plasma histamine and serum tryptase have been reported, consistent with mast cell activation. There is some evidence that corticosteroids reduce the frequency and severity of episodes of IA, consistent with a steroid‐responsive condition. Important differential diagnoses of IA include galactose alpha‐1,3 galactose (a carbohydrate contained in red meat) allergy, pigeon tick bite (Argax reflexus), wheat‐dependent exercise‐induced anaphylaxis, Anisakis simplex allergy and mast cell disorders. Other differential diagnoses include “allergy‐mimics” such as asthma masquerading as anaphylaxis, undifferentiated somatoform disorder, panic attacks, globus hystericus, vocal cord dysfunction, scombroid poisoning, vasoactive amine intolerance, carcinoid syndrome and phaeochromocytoma. Acute treatment of IA is the same as for other forms of anaphylaxis. Long‐term management is individualized and dictated by frequency and severity of symptoms and involves treatment with H1 and H2 receptor blockers, leukotriene receptor antagonist and consideration for prolonged reducing courses of oral corticosteroids. Patients should possess an epinephrine autoinjector with an anaphylaxis self‐management plan. There are anecdotal reports regarding the use of omalizumab. For reasons that remain unclear, the prognosis of IA is generally favourable with appropriate treatment and patient education. If remission cannot be achieved, the diagnosis should be reconsidered.
doi_str_mv 10.1111/cea.13402
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2247925038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2247925038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4192-6a00782ee5601e9cdf239174d601bea8066b6473a48966d3dc47c1a165199f493</originalsourceid><addsrcrecordid>eNp1kDFPwzAQRi0EoqEwsDAiJCaGtHe2Y8djFRWoVIkFZstxHDVV2oS4EeTfY0hh41tOJz29032EXCPMMGRunZkh40BPSIRMJDENOSURqITHMlV8Qi683wIAS1R6TiYMASgqEZGbVVE1rTlsKntn9qbdDLX5rPwlOStN7d3VcU7J2-PyNXuO1y9Pq2yxji1HRWNhAGRKnUsEoFO2KClTKHkR1tyZFITIBZfM8FQJUbDCcmnRoEhQqZIrNiX3o7ftmvfe-YPeNn23Dyc1pVwqmgBLA_UwUrZrvO9cqduu2plu0Aj6uwEdGtA_DQT29mjs850r_sjflwMwH4GPqnbD_yadLRej8gsGPWD0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2247925038</pqid></control><display><type>article</type><title>Idiopathic anaphylaxis</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bilò, Maria Beatrice ; Martini, Matteo ; Tontini, Chiara ; Mohamed, Omar E. ; Krishna, Mamidipudi T.</creator><creatorcontrib>Bilò, Maria Beatrice ; Martini, Matteo ; Tontini, Chiara ; Mohamed, Omar E. ; Krishna, Mamidipudi T.</creatorcontrib><description>Idiopathic anaphylaxis (IA) or spontaneous anaphylaxis is a diagnosis of exclusion when no cause can be identified. The exact incidence and prevalence of IA are not known. The clinical manifestations of IA are similar to other known causes of anaphylaxis. A typical attack is usually acute in onset and can worsen over minutes to a few hours. The pathophysiology of IA has not yet been fully elucidated, although an IgE‐mediated pathway by hitherto unidentified trigger/s might be the main underlying mechanism. Elevated concentrations of urinary histamine and its metabolite, methylimidazole acetic acid, plasma histamine and serum tryptase have been reported, consistent with mast cell activation. There is some evidence that corticosteroids reduce the frequency and severity of episodes of IA, consistent with a steroid‐responsive condition. Important differential diagnoses of IA include galactose alpha‐1,3 galactose (a carbohydrate contained in red meat) allergy, pigeon tick bite (Argax reflexus), wheat‐dependent exercise‐induced anaphylaxis, Anisakis simplex allergy and mast cell disorders. Other differential diagnoses include “allergy‐mimics” such as asthma masquerading as anaphylaxis, undifferentiated somatoform disorder, panic attacks, globus hystericus, vocal cord dysfunction, scombroid poisoning, vasoactive amine intolerance, carcinoid syndrome and phaeochromocytoma. Acute treatment of IA is the same as for other forms of anaphylaxis. Long‐term management is individualized and dictated by frequency and severity of symptoms and involves treatment with H1 and H2 receptor blockers, leukotriene receptor antagonist and consideration for prolonged reducing courses of oral corticosteroids. Patients should possess an epinephrine autoinjector with an anaphylaxis self‐management plan. There are anecdotal reports regarding the use of omalizumab. For reasons that remain unclear, the prognosis of IA is generally favourable with appropriate treatment and patient education. If remission cannot be achieved, the diagnosis should be reconsidered.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1111/cea.13402</identifier><identifier>PMID: 31002196</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acetic acid ; Allergies ; Anaphylaxis ; angio‐oedema ; Asthma ; Carbohydrates ; Cell activation ; Corticoids ; Corticosteroids ; Diagnosis ; drug allergy ; Edema ; Epinephrine ; Food allergies ; food allergy ; Galactose ; Histamine ; Immunoglobulin E ; Intolerance ; mast cells ; Meat ; Monoclonal antibodies ; Patients ; Pheochromocytoma ; Remission ; Somatoform disorders ; Steroids ; Tryptase ; Vasoactive agents ; venom and insect allergy ; Wheat</subject><ispartof>Clinical and experimental allergy, 2019-07, Vol.49 (7), p.942-952</ispartof><rights>2019 John Wiley &amp; Sons Ltd</rights><rights>2019 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2019 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4192-6a00782ee5601e9cdf239174d601bea8066b6473a48966d3dc47c1a165199f493</citedby><cites>FETCH-LOGICAL-c4192-6a00782ee5601e9cdf239174d601bea8066b6473a48966d3dc47c1a165199f493</cites><orcidid>0000-0001-9873-9695 ; 0000-0002-9324-6039</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcea.13402$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcea.13402$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31002196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bilò, Maria Beatrice</creatorcontrib><creatorcontrib>Martini, Matteo</creatorcontrib><creatorcontrib>Tontini, Chiara</creatorcontrib><creatorcontrib>Mohamed, Omar E.</creatorcontrib><creatorcontrib>Krishna, Mamidipudi T.</creatorcontrib><title>Idiopathic anaphylaxis</title><title>Clinical and experimental allergy</title><addtitle>Clin Exp Allergy</addtitle><description>Idiopathic anaphylaxis (IA) or spontaneous anaphylaxis is a diagnosis of exclusion when no cause can be identified. The exact incidence and prevalence of IA are not known. The clinical manifestations of IA are similar to other known causes of anaphylaxis. A typical attack is usually acute in onset and can worsen over minutes to a few hours. The pathophysiology of IA has not yet been fully elucidated, although an IgE‐mediated pathway by hitherto unidentified trigger/s might be the main underlying mechanism. Elevated concentrations of urinary histamine and its metabolite, methylimidazole acetic acid, plasma histamine and serum tryptase have been reported, consistent with mast cell activation. There is some evidence that corticosteroids reduce the frequency and severity of episodes of IA, consistent with a steroid‐responsive condition. Important differential diagnoses of IA include galactose alpha‐1,3 galactose (a carbohydrate contained in red meat) allergy, pigeon tick bite (Argax reflexus), wheat‐dependent exercise‐induced anaphylaxis, Anisakis simplex allergy and mast cell disorders. Other differential diagnoses include “allergy‐mimics” such as asthma masquerading as anaphylaxis, undifferentiated somatoform disorder, panic attacks, globus hystericus, vocal cord dysfunction, scombroid poisoning, vasoactive amine intolerance, carcinoid syndrome and phaeochromocytoma. Acute treatment of IA is the same as for other forms of anaphylaxis. Long‐term management is individualized and dictated by frequency and severity of symptoms and involves treatment with H1 and H2 receptor blockers, leukotriene receptor antagonist and consideration for prolonged reducing courses of oral corticosteroids. Patients should possess an epinephrine autoinjector with an anaphylaxis self‐management plan. There are anecdotal reports regarding the use of omalizumab. For reasons that remain unclear, the prognosis of IA is generally favourable with appropriate treatment and patient education. If remission cannot be achieved, the diagnosis should be reconsidered.</description><subject>Acetic acid</subject><subject>Allergies</subject><subject>Anaphylaxis</subject><subject>angio‐oedema</subject><subject>Asthma</subject><subject>Carbohydrates</subject><subject>Cell activation</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Diagnosis</subject><subject>drug allergy</subject><subject>Edema</subject><subject>Epinephrine</subject><subject>Food allergies</subject><subject>food allergy</subject><subject>Galactose</subject><subject>Histamine</subject><subject>Immunoglobulin E</subject><subject>Intolerance</subject><subject>mast cells</subject><subject>Meat</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pheochromocytoma</subject><subject>Remission</subject><subject>Somatoform disorders</subject><subject>Steroids</subject><subject>Tryptase</subject><subject>Vasoactive agents</subject><subject>venom and insect allergy</subject><subject>Wheat</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kDFPwzAQRi0EoqEwsDAiJCaGtHe2Y8djFRWoVIkFZstxHDVV2oS4EeTfY0hh41tOJz29032EXCPMMGRunZkh40BPSIRMJDENOSURqITHMlV8Qi683wIAS1R6TiYMASgqEZGbVVE1rTlsKntn9qbdDLX5rPwlOStN7d3VcU7J2-PyNXuO1y9Pq2yxji1HRWNhAGRKnUsEoFO2KClTKHkR1tyZFITIBZfM8FQJUbDCcmnRoEhQqZIrNiX3o7ftmvfe-YPeNn23Dyc1pVwqmgBLA_UwUrZrvO9cqduu2plu0Aj6uwEdGtA_DQT29mjs850r_sjflwMwH4GPqnbD_yadLRej8gsGPWD0</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Bilò, Maria Beatrice</creator><creator>Martini, Matteo</creator><creator>Tontini, Chiara</creator><creator>Mohamed, Omar E.</creator><creator>Krishna, Mamidipudi T.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0001-9873-9695</orcidid><orcidid>https://orcid.org/0000-0002-9324-6039</orcidid></search><sort><creationdate>201907</creationdate><title>Idiopathic anaphylaxis</title><author>Bilò, Maria Beatrice ; Martini, Matteo ; Tontini, Chiara ; Mohamed, Omar E. ; Krishna, Mamidipudi T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4192-6a00782ee5601e9cdf239174d601bea8066b6473a48966d3dc47c1a165199f493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetic acid</topic><topic>Allergies</topic><topic>Anaphylaxis</topic><topic>angio‐oedema</topic><topic>Asthma</topic><topic>Carbohydrates</topic><topic>Cell activation</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Diagnosis</topic><topic>drug allergy</topic><topic>Edema</topic><topic>Epinephrine</topic><topic>Food allergies</topic><topic>food allergy</topic><topic>Galactose</topic><topic>Histamine</topic><topic>Immunoglobulin E</topic><topic>Intolerance</topic><topic>mast cells</topic><topic>Meat</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pheochromocytoma</topic><topic>Remission</topic><topic>Somatoform disorders</topic><topic>Steroids</topic><topic>Tryptase</topic><topic>Vasoactive agents</topic><topic>venom and insect allergy</topic><topic>Wheat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilò, Maria Beatrice</creatorcontrib><creatorcontrib>Martini, Matteo</creatorcontrib><creatorcontrib>Tontini, Chiara</creatorcontrib><creatorcontrib>Mohamed, Omar E.</creatorcontrib><creatorcontrib>Krishna, Mamidipudi T.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilò, Maria Beatrice</au><au>Martini, Matteo</au><au>Tontini, Chiara</au><au>Mohamed, Omar E.</au><au>Krishna, Mamidipudi T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Idiopathic anaphylaxis</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clin Exp Allergy</addtitle><date>2019-07</date><risdate>2019</risdate><volume>49</volume><issue>7</issue><spage>942</spage><epage>952</epage><pages>942-952</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Idiopathic anaphylaxis (IA) or spontaneous anaphylaxis is a diagnosis of exclusion when no cause can be identified. The exact incidence and prevalence of IA are not known. The clinical manifestations of IA are similar to other known causes of anaphylaxis. A typical attack is usually acute in onset and can worsen over minutes to a few hours. The pathophysiology of IA has not yet been fully elucidated, although an IgE‐mediated pathway by hitherto unidentified trigger/s might be the main underlying mechanism. Elevated concentrations of urinary histamine and its metabolite, methylimidazole acetic acid, plasma histamine and serum tryptase have been reported, consistent with mast cell activation. There is some evidence that corticosteroids reduce the frequency and severity of episodes of IA, consistent with a steroid‐responsive condition. Important differential diagnoses of IA include galactose alpha‐1,3 galactose (a carbohydrate contained in red meat) allergy, pigeon tick bite (Argax reflexus), wheat‐dependent exercise‐induced anaphylaxis, Anisakis simplex allergy and mast cell disorders. Other differential diagnoses include “allergy‐mimics” such as asthma masquerading as anaphylaxis, undifferentiated somatoform disorder, panic attacks, globus hystericus, vocal cord dysfunction, scombroid poisoning, vasoactive amine intolerance, carcinoid syndrome and phaeochromocytoma. Acute treatment of IA is the same as for other forms of anaphylaxis. Long‐term management is individualized and dictated by frequency and severity of symptoms and involves treatment with H1 and H2 receptor blockers, leukotriene receptor antagonist and consideration for prolonged reducing courses of oral corticosteroids. Patients should possess an epinephrine autoinjector with an anaphylaxis self‐management plan. There are anecdotal reports regarding the use of omalizumab. For reasons that remain unclear, the prognosis of IA is generally favourable with appropriate treatment and patient education. If remission cannot be achieved, the diagnosis should be reconsidered.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31002196</pmid><doi>10.1111/cea.13402</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9873-9695</orcidid><orcidid>https://orcid.org/0000-0002-9324-6039</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0954-7894
ispartof Clinical and experimental allergy, 2019-07, Vol.49 (7), p.942-952
issn 0954-7894
1365-2222
language eng
recordid cdi_proquest_journals_2247925038
source Wiley Online Library Journals Frontfile Complete
subjects Acetic acid
Allergies
Anaphylaxis
angio‐oedema
Asthma
Carbohydrates
Cell activation
Corticoids
Corticosteroids
Diagnosis
drug allergy
Edema
Epinephrine
Food allergies
food allergy
Galactose
Histamine
Immunoglobulin E
Intolerance
mast cells
Meat
Monoclonal antibodies
Patients
Pheochromocytoma
Remission
Somatoform disorders
Steroids
Tryptase
Vasoactive agents
venom and insect allergy
Wheat
title Idiopathic anaphylaxis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T02%3A35%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Idiopathic%20anaphylaxis&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=Bil%C3%B2,%20Maria%20Beatrice&rft.date=2019-07&rft.volume=49&rft.issue=7&rft.spage=942&rft.epage=952&rft.pages=942-952&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1111/cea.13402&rft_dat=%3Cproquest_cross%3E2247925038%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2247925038&rft_id=info:pmid/31002196&rfr_iscdi=true